In a patient with chronic respiratory failure who is currently taking losartan 100 mg daily and is allergic to lisinopril, which cardio‑selective β‑blocker is the appropriate next antihypertensive option?

Cardioselective Beta-Blockers Are the Appropriate Next Antihypertensive Option

In a patient with chronic respiratory failure currently on losartan 100 mg daily with a lisinopril allergy, add a cardioselective β-blocker—specifically bisoprolol 1.25 mg daily or metoprolol succinate 12.5-25 mg daily—as these agents are preferred in patients with bronchospastic airway disease requiring beta-blocker therapy. 1, 2

Rationale for Cardioselective Beta-Blockers in Respiratory Disease

The 2017 ACC/AHA Hypertension Guidelines explicitly state that cardioselective beta-blockers (atenolol, betaxolol, bisoprolol, metoprolol tartrate, metoprolol succinate) are preferred in patients with bronchospastic airway disease requiring a beta blocker 1, 2, 3. This is critical for your patient with chronic respiratory failure.

Why Cardioselectivity Matters

• Beta-1 selectivity minimizes bronchospasm risk: Cardioselective agents preferentially block cardiac beta-1 receptors while relatively sparing pulmonary beta-2 receptors that mediate bronchodilation 1, 2
• Non-cardioselective agents (nadolol, propranolol) should be avoided in patients with reactive airways disease 1, 2, 3
• Recent evidence confirms that cardioselective beta-blockers are safe in COPD and may even reduce exacerbations 4

Specific Agent Selection

Start with either:

• Bisoprolol 1.25 mg once daily, titrating to target 10 mg daily 1, 2
• Metoprolol succinate 12.5-25 mg once daily, titrating to target 200 mg daily 1, 2

These two agents are specifically highlighted as preferred in patients with heart failure with reduced ejection fraction (HFrEF) 1, 2, 5, though beta-blockers are not first-line for hypertension alone unless there are compelling indications like ischemic heart disease or heart failure 1, 2.

Alternative Cardioselective Options

• Nebivolol 5 mg daily (cardioselective with vasodilatory properties via nitric oxide) 1, 2
• Atenolol 25 mg twice daily (though less preferred due to lack of mortality benefit data) 1

Critical Safety Considerations

Avoid Non-Cardioselective Agents

Do not use nadolol, propranolol, or carvedilol in this patient—the guidelines explicitly state to "avoid in patients with reactive airways disease" 1, 2, 3. While carvedilol is preferred in HFrEF, it has combined alpha- and beta-receptor blocking properties and is non-cardioselective 1.

Titration Strategy

• Start at the lowest dose shown above
• Monitor for worsening respiratory symptoms, bradycardia, and hypotension
• Increase dose every 1-2 weeks if tolerated 6
• Never abruptly discontinue—taper to avoid rebound hypertension 1, 2

Monitoring Parameters

• Heart rate (watch for excessive bradycardia <50 bpm)
• Blood pressure (current BP on losartan 100 mg should guide aggressiveness)
• Respiratory symptoms (increased dyspnea, wheezing, need for bronchodilators)
• If bronchospasm develops despite cardioselectivity, discontinue and consider alternative classes

Why Not Other Drug Classes?

Already Maximized ARB Therapy

Your patient is on losartan 100 mg daily, which is the maximum dose 7. The guidelines state not to combine ACE inhibitors with ARBs due to increased cardiovascular and renal risk 2. Given the lisinopril allergy (likely angioedema), ACE inhibitors are permanently contraindicated 1.

Calcium Channel Blockers as Alternative

If beta-blockers are not tolerated, amlodipine or felodipine (dihydropyridine CCBs) would be reasonable alternatives 1, 3. However, beta-blockers may provide additional cardiovascular protection if the patient has underlying coronary disease.

Diuretics

Adding a thiazide or thiazide-like diuretic (chlorthalidone 12.5-25 mg daily or hydrochlorothiazide 12.5-25 mg daily) is also reasonable 1, 2, particularly if volume overload contributes to hypertension. However, the question specifically asks about beta-blockers as the next option.

Common Pitfalls to Avoid

1. Do not assume all beta-blockers are contraindicated in respiratory disease—only non-cardioselective agents pose significant risk 4
2. Do not use beta-blockers with intrinsic sympathomimetic activity (acebutolol, penbutolol, pindolol) as they are "generally avoided, especially in patients with IHD or HF" 1, 2
3. Do not start at high doses—begin low and titrate slowly to minimize adverse effects 6
4. Do not combine with non-dihydropyridine CCBs (diltiazem, verapamil) due to increased risk of bradycardia and heart block 1, 3